TX-PLANVIEW
Planview, a global leader in Portfolio Management and Work Management solutions, today published a global report that unlocks how companies are successfully responding to continuous market disruption, accelerating innovation and executing on their business strategies. Based on a first-of-its-kind study, the report, titled “The State of Strategy Execution: Embracing Uncertainty to Adapt at Speed ,” uncovers why many companies are challenged to pivot strategy in times of change, and provides pragmatic recommendations for companies to adapt more quickly to shifting conditions and disruptive events, and deliver quality business outcomes.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210324005214/en/
“This study was designed to answer a deceptively simple question: Why can some companies quickly adapt and even accelerate strategy execution during times of significant change, and others just get by?,” said Patrick Tickle, Chief Product Officer at Planview. “That question is of utmost importance not only today while we navigate the pandemic but for the foreseeable future. Market disruptions are no longer the exception. Disruption is the norm, and the smartest companies have learned how to not just survive but thrive in environments of constant change.”
Segmenting respondents into categories of Leaders, Challengers and Laggards, a clear picture emerged of what successful companies are doing and that others can replicate, including:
- Prioritizing speed when it comes to making decisions and executing faster
- Implementing technology that delivers faster business insights from data
- Adjusting strategies, funding, and operating plans with short-interval planning cycles
- Improving the prioritization process to realign resources to the most important work
- Utilizing Lean and Agile business practices throughout the organization
This vital report goes beyond just analyzing why some organizations are more successful than others in quickly adapting to market disruptions. It provides a roadmap for how other companies can achieve success, streamline business processes to prioritize speed and quality, accelerate innovation, and improve strategic outcomes.
“Reducing the gap between strategy and execution becomes even more important as the pace of external disruption increases, and this report provides a clear blueprint about how leading companies are doing exactly that,” said Tickle. “We found that the most successful companies are following a similar recipe for success. They are building speed into their business operations to adjust to constant change. They have shorter, more adaptable planning cycles that enable them to respond to shifts in real-time. They remove internal barriers that stand in the way of adaptability. They resist the lure of the status quo. And they use technology and agile processes to build speed and quality into the way they execute on strategy.”
Based on a global benchmarking analysis of nearly 1,000 business and technology professionals at organizations across a wide range of industries around the world, the survey was commissioned by Planview and conducted by independent research firm Lawless Research. Results uncovered why many companies struggle to quickly respond to change and disruption:
- Complex governance or approval processes (38%)
- Unclear or conflicting priorities (33%)
- Lack of resources to complete all approved projects (31%)
- Lack of organizational alignment (departmental silos) (31%)
To read the full report and its detailed set of recommendations, visit: The State of Strategy Execution: Embracing Uncertainty to Adapt at Speed . To get more insights into the best practices utilized by many of the successful companies in the benchmarking study, visit: Managing Transformation: Connect Strategy to Delivery to Dynamic Business Today .
Survey Methodology
Planview commissioned a survey, undertaken by an independent research organization, Lawless Research, in December 2020. Nearly 1,000 business and technology professionals across multiple countries were surveyed, including: Australia, France, Germany, United States, and the UK. Companies were from a range of industries, including banking and financial, technology, retail, manufacturing, healthcare, business services, government and public sector, travel and hospitality, engineering, and more. The corresponding report provides pragmatic recommendations for business, technology, and finance leaders seeking to create a tight connection between strategy and execution, adapt more quickly to shifting conditions and disruptive events, and deliver quality business outcomes.
About Planview
Planview has one focus: enabling the transformation journey as organizations rewire strategy to delivery in today’s fast-paced, highly disruptive markets. Our solutions enable organizations to navigate this journey and accelerate on-strategy delivery at enterprise scale. Planview’s full spectrum of Portfolio Management and Work Management solutions create organizational focus on the strategic outcomes that matter and empower teams to deliver their best work, no matter how they work. The comprehensive Planview platform and enterprise success model enable customers to deliver innovative, competitive products, services, and customer experiences. Headquartered in Austin, Texas, Planview has more than 1,000 employees supporting 4,500 customers and 1.3 million users worldwide. For more information, visit: www.planview.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210324005214/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CorriXR Therapeutics, InhaTarget Therapeutics, and Merxin Ltd Announce Strategic Collaboration for the Development of Inhaled Lung Cancer Treatment2.12.2025 14:30:00 CET | Press release
CorriXR Therapeutics, an oncology-focused biotherapeutics company pioneering a ground-breaking gene editing platform technology, InhaTarget Therapeutics, a company dedicated to the early development and clinical validation of innovative treatments of pulmonary diseases by inhalation, and Merxin Ltd, a designer and supplier of inhaler devices, have entered a strategic collaboration to develop a pioneering inhaled genetic therapy targeting lung cancer. The partnership draws upon CorriXR’s proprietary CRISPR-based gene editing platform targeting NRF2, InhaTarget’s proprietary formulation platform and strong experience in pulmonary drug development, and Merxin Ltd’s advanced inhalation device technology. Through their combined expertise, they aim to create a patient-friendly inhaled therapy that delivers targeted treatment directly to lung tumors, maximizing efficacy, minimizing systemic side effects, and offering new hope for patients facing one of the world’s deadliest cancers. Innovativ
Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies2.12.2025 14:00:00 CET | Press release
Aurigene Oncology Limited, a clinical-stage biopharmaceutical company developing novel therapies in oncology,today announced initial clinical results from 1st two cohorts of its ongoing Phase 1 clinical trial evaluating AUR112 in patients with relapsed or refractory lymphoid malignancies. Early findings show that AUR112 is safe, well tolerated, demonstrating meaningful clinical activity, with objective responses observed across multiple lymphoma subtypes, including Mantle Cell Lymphoma (MCL) and Marginal Zone Lymphoma (MZL). “We are very encouraged by the early results of the first two cohorts from our Phase 1 study of AUR112,” said Dr. Murali Ramachandra, CEO. “AUR112 has shown a promising initial clinical profile, achieving an overall response rate of 63.6% in the efficacy-evaluable population and 58.3% in the intent-to-treat group. These strong early data, combined with its distinct preclinical and safety characteristics, reinforce our belief that AUR112 has the potential to become
AdvanCell Initiates Phase 2 Expansion Trial of ADVC001, a Novel Targeted Alpha Therapy for Prostate Cancer2.12.2025 14:00:00 CET | Press release
Clinical development of 212Pb-ADVC001 (ADVC001) is advancing rapidly with encouraging Phase 1b data presented at ESMO 2025 The Phase 2 expansion will evaluate 160 MBq and 200 MBq doses of ADVC001 using a randomized, multi-dose-response design and adaptive dosing strategies to optimize clinical outcomes across three indications: metastatic hormone-sensitive prostate cancer (mHSPC) and metastatic castration-resistant prostate cancer (mCRPC) in pre-chemotherapy and post-177Lu-PSMA radioligand therapy (RLT) settings AdvanCell, a clinical-stage radiopharmaceutical company developing innovative targeted alpha therapies for cancer, today announced the initiation of the TheraPb Phase 2 expansion trial (NCT05720130) evaluating its lead investigational candidate, ADVC001, in metastatic prostate cancer. The news follows the encouraging Phase 1b dose escalation results presented at the European Society for Medical Oncology (ESMO) 2025 congress that showed a favorable safety profile and compelling
Luma AI Opens for International Business With Former WPP Executive Jason Day Leading New London Office2.12.2025 14:00:00 CET | Press release
Establishment of the London office follows Luma AI’s $900 million Series C investment led by HUMAIN - marking the company’s first major step towards international scale with plans to deepen partnerships across the UK, European Union, and Saudi Arabia in the first phase of expansion.Former Monks and WPP executive Jason Day was appointed Head of EMEA to launch Luma AI internationally and drive worldwide growth across creative, advertising, gaming, and entertainment sectors.Luma AI plans to add 200 new jobs in London in 2026. Luma AI, the frontier artificial intelligence company building multimodal AGI intelligence and known for its flagship product Dream Machine, today announced a major step in its global expansion with the opening of its first international office in London, UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251202217704/en/ LUMA AI OPENS FOR INTERNATIONAL BUSINESS WITH FORMER WPP EXECUTIVE JASON DAY LEADING
Eventbrite Enters into Definitive Agreement to Be Acquired by Bending Spoons for Roughly $500 Million to Accelerate Eventbrite’s Next Phase of Growth2.12.2025 13:30:00 CET | Press release
Eventbrite stockholders to receive $4.50 per share in cash Eventbrite, Inc. (NYSE: EB), the leading global marketplace for shared experiences, announced today that it has entered into a definitive agreement to be acquired by Bending Spoons, in an all-cash transaction valued at approximately $500 million. The acquisition is subject to customary closing conditions and approvals, including regulatory approvals and approval by Eventbrite’s stockholders. “For two decades, Eventbrite has stood at the forefront of the experience economy, helping tens of millions to create, discover, and attend unforgettable events,” said Luca Ferrari, Bending Spoons CEO and Co-Founder. “Joining forces with Bending Spoons will accelerate innovation and strengthen Eventbrite’s tools and resources to bring even more people together through shared live experiences for many years to come. As longstanding fans, we’ve identified a few opportunities that we’re excited about exploring with the Eventbrite team after cl
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
